PPARG and Mental deterioration: Observational studies have shown that PPAR-γ agonists have a protective effect against cognitive decline in diabetic patients (HR = 0.91, 95% CI = [0.88, 0.94] and I2 = 39.5%), where the heterogeneity of the data was acceptable.